US · BTX
BlackRock Technology and Private Equity Term Trust
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- blackrock.com
Price · as of 2024-12-31
$8.05
Market cap 766.79M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $22.39 | +178.14% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $6.92 | ||||
| 2022 | $5.09 | $25.99 | |||
| 2023 | $6.29 | $25.97 | |||
| 2024 | $5.94 | $22.39 |
AI valuation
Our deep-learning model estimates BlackRock Technology and Private Equity Term Trust's (BTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $22.39
- Current price
- $8.05
- AI upside
- +178.14%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BTX | BlackRock Technology and … | $8.05 | 766.79M | +178% | — | — | — | 35.90 | 0.72 | 31.50 | — | — | 0.72 | 100.00% | 87.75% | 87.75% | 1.87% | 1.87% | 1.84% | 0.00 | 2313.25 | — | — | — | -8265.00% | -8113.00% | 2800.00% | 21.63% | — | 14.55% | 14.41% | 517.40% | 21.63% | 35.90 | 4.62 | 31.50 | 31.17 |
| CRMD | CorMedix Inc. | $7.13 | 561.77M | — | +1,092,258% | — | — | -35.17 | 7.45 | 14.50 | -30.53 | — | 7.61 | 92.66% | -51.43% | -41.24% | -23.17% | -146.77% | -17.85% | 0.01 | -614.10 | 3.39 | 3.05 | 2.11 | -6703.00% | — | 3096.00% | -8.05% | -1.50 | -358.96% | 0.00% | 0.00% | 0.00% | -25.91 | -11.42 | 13.33 | 7.62 |
| GHRS | GH Research PLC | $14.85 | 921.14M | — | — | — | — | -14.02 | 3.05 | — | -10.30 | -136.21 | 3.05 | 0.00% | — | — | -19.58% | -113.53% | -18.80% | 0.00 | -70.17 | 17.23 | 16.87 | 2.60 | 1029.00% | — | 2661.00% | -7.75% | -4.72 | -95.53% | 0.00% | 0.00% | 4.16% | -7.90 | -9.39 | — | 34.41 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| LENZ | LENZ Therapeutics, Inc. | $13.49 | 422.1M | — | — | — | — | -10.13 | 2.47 | — | -5.96 | — | 2.47 | 0.00% | — | — | -89.37% | 72.47% | -34.84% | 0.01 | — | 20.36 | 20.09 | 0.38 | -8471.00% | — | -91.00% | -11.88% | -5.71 | 74.02% | 0.00% | 0.00% | 0.00% | -5.06 | -4.95 | — | 26.23 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TBPH | Theravance Biopharma, Inc… | $18.25 | 924.77M | +61% | -73% | — | — | -8.25 | 2.65 | 7.23 | -11.10 | -55.01 | 2.65 | 100.00% | -72.92% | -87.63% | -29.04% | -31.64% | -15.33% | 0.28 | -18.44 | 5.02 | 4.89 | -0.31 | 1500.00% | 1212.00% | -5975.00% | -2.55% | -0.36 | -8.00% | 0.00% | 0.00% | 0.67% | -9.09 | -35.98 | 6.63 | -2.07 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
About BlackRock Technology and Private Equity Term Trust
BlackRock Innovation and Growth Trust (the Trust) is a newly-organized, non-diversified, closed-end management investment company with no operating history. The Trusts investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. There can be no assurance that the Trusts investment objectives will be achieved or that the Trusts investment program will be successful The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Trusts adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trusts adviser focuses on mid- and small-capitalization growth companies that are innovative. These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace.
- CEO
- John M. Perlowski
- Employees
- 0
- Beta
- 1.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $8.05) − 1 = — (DCF, example).